Why a COVID-19 trial is exciting BOD (ASX:BOD) investors today?

A clinical trial into the use of medicinal cannabis for long-term COVID-19 is going ahead.

| More on:
ASX Pot Stocks

Image Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The BOD Australia share price is up nearly 7%
  • The company’s announced a new trial on treatment for long term COVID-19
  • It involves a medicinal cannabis product

The BOD Australia Ltd (ASX: BOD) share price is surging today amid news of a new COVID-19 clinical trial.

The company’s shares are currently swapping hands at 23.5 cents, up 6.82%.

Let’s take a look at what the company announced today?

Medicinal cannabis to treat COVID-19?

BOD investors are reacting to news of a clinical trial into the use of medicinal cannabis to treat long term COVID-19.

The company will work with Drug Science UK on the six-month trial featuring BOD’s flagship product MediCabilis.

Symptoms of long term COVID-19 include chronic pain, anxiety, fatigue, and sleeping trouble. The trial will recruit 30 people suffering from the condition.

BOD is hopeful it will be able to commercialise its product in the UK and “other countries” if the trial is successful.

About 1.3 million people are estimated to have long-COVID-19 in the UK with 1 in 40 of these having symptoms lasting three months or more.

BOD said its MediCabilis product is already prescribed to treat people with long-COVID-19 symptoms including anxiety, sleep disorders, and chronic pain.

Management comment

Speaking on the news of the trial, CEO Jo Patterson said:

While there aren’t any existing treatments for long-COVID, our medicinal cannabis products have been used to treat and alleviate a number of similar conditions.

We anticipate that this clinical trial will provide us with great insight into its potential to treat long-COVID and build on the body of evidence for the use of cannabis-based medicines, in place of other pharmaceuticals.

Share price snapshot

The BOD share price has crashed by 50% in the past year. Despite this, it is up 4% in the last month and nearly 7% in the past week.

In comparison, the S&P/ASX 200 Index (ASX: XJO) has returned more than 10% to investors in the past year.

The company commands a market capitalisation of about 24.9 million based on the current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

Up 38% in a month, what’s sparking the recent Race Oncology share price run-up?

What a month it has been for Race Oncology shareholders.

Read more »

Three businesspeople leap high with the CBD in the background.
Healthcare Shares

Why is the Nanosonics share price jumping 10% on Wednesday?

Nanosonics shares are jumping on Wednesday...

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Healthcare Shares

Why this broker is tipping the ResMed share price to rise 17%

A leading broker says ResMed shares can rise strongly from here...

Read more »

patient with doctor, medical company, medical insurance
Healthcare Shares

Beating the benchmark: Why this broker is betting on the CSL share price for outperformance

Could plasma demand boost the CSL share price?

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Here’s what happened to the CSL share price in June

CSL shares were relatively positive performers in June...

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Up 13% in a month, Polynovo share price bounces back after being dumped from ASX 200

What's going on with the Polynovo share price?

Read more »

health workers shake hands and congratulate each other on good news
Share Gainers

This ASX All Ordindaries healthcare share is ripping 17% higher amid a new contract win

Investors seem to like the contract win from this healthcare player.

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

Here’s how ASX 200 healthcare shares performed in June

Healthcare shares were a tad ill in June.

Read more »